Search

CN-121987659-A - Composite polysaccharide preparation for treating diabetes and application thereof

CN121987659ACN 121987659 ACN121987659 ACN 121987659ACN-121987659-A

Abstract

The invention discloses a compound polysaccharide preparation for treating diabetes and application thereof, belonging to the technical field of biomedicine. The compound polysaccharide preparation consists of compound polysaccharide A and compound polysaccharide B according to the mass ratio of 1:1. The compound polysaccharide A is prepared from okra and chlorella by alkaline ultrasonic extraction and 10-100kDa ultrafiltration fractionation, and the compound polysaccharide B is prepared from grifola frondosa and black tiger palm fungus by enzymolysis and hot water extraction. Experiments prove that the preparation can obviously improve insulin secretion and glucose uptake capacity of islet cells through strong synergism among components, effectively reduce fasting blood glucose of a type 2 diabetes model mouse, and synchronously improve triglyceride and total cholesterol levels. The preparation of the invention has natural sources, is safe and efficient, thereby providing a new choice for the drug development of type 2 diabetes.

Inventors

  • MA WENJING
  • WANG RUI
  • CHEN YUHANG
  • CHENG YUANYUAN

Assignees

  • 济南瑞隆安生物技术有限公司

Dates

Publication Date
20260508
Application Date
20260318

Claims (10)

  1. 1. A compound polysaccharide preparation for treating diabetes, which is characterized by being prepared from compound polysaccharide A and compound polysaccharide B; the compound polysaccharide A is prepared from okra fruits and chlorella through alkaline ultrasonic extraction, deproteinization, ultrafiltration fractionation and freeze drying; The compound polysaccharide B is prepared from grifola frondosa and black tiger palm fungus through alcohol extraction degreasing, enzymolysis, hot water extraction, alcohol precipitation and freeze drying; The mass ratio of the compound polysaccharide A to the compound polysaccharide B is 1-3:1-3.
  2. 2. The complex polysaccharide formulation according to claim 1, wherein the diabetes is type 2 diabetes.
  3. 3. The complex polysaccharide preparation according to claim 2, wherein the mass ratio of complex polysaccharide a to complex polysaccharide B is 1:1.
  4. 4. A complex polysaccharide preparation according to claim 3, characterized in that the preparation method of complex polysaccharide a comprises the following steps: (1) Mixing okra fruit powder and chlorella powder according to a mass ratio of 3:1 to obtain mixed powder a; (2) Adding 0.1 mol/L NaOH solution according to a feed liquid ratio of 1:20-30 g/mL, performing ultrasonic treatment at 40-50 ℃ for 30-50 minutes, and centrifugally collecting supernatant; (3) Deproteinizing the supernatant and adjusting the pH to neutrality to obtain polysaccharide extract; (4) Filtering with ultrafiltration membrane with molecular weight cut-off of 100kDa, and collecting permeate; (5) And filtering the permeate through an ultrafiltration membrane with the molecular weight cutoff of 10kDa, collecting the retentate, and drying to obtain the compound polysaccharide A.
  5. 5. The complex polysaccharide preparation according to claim 4, wherein the preparation method of the complex polysaccharide B comprises the following steps: (a) Mixing grifola frondosa powder and black tiger palm fungus powder according to a mass ratio of 2:1 to obtain mixed powder b; (b) Reflux degreasing with 80% ethanol solution, and collecting residue; (c) Deionized water is added according to the ratio of 1:20-30 g/mL, the pH is adjusted to 5.0-6.0, and cellulase and papain are added for enzymolysis; (d) After enzyme deactivation, extracting with 95 ℃ hot water for 1 hour, centrifuging to obtain supernatant, concentrating, precipitating with 75% ethanol, collecting precipitate, and freeze-drying to obtain compound polysaccharide B.
  6. 6. Use of a complex polysaccharide formulation according to any one of claims 1-5 for the preparation of a medicament for diabetes.
  7. 7. The use according to claim 6, wherein the diabetes is type 2 diabetes.
  8. 8. The use according to claim 7, wherein the medicament is for increasing secretion capacity of islet cells, increasing uptake capacity of islet cells, reducing fasting blood glucose levels and improving blood lipid levels.
  9. 9. A medicament for improving type 2 diabetes mellitus, which is characterized by consisting of a compound polysaccharide preparation and a pharmaceutically acceptable carrier; the compound polysaccharide preparation is prepared from compound polysaccharide A and compound polysaccharide B according to a mass ratio of 1:1; The compound polysaccharide A is prepared by the preparation method of claim 4; the compound polysaccharide B is prepared by the preparation method of claim 5.
  10. 10. The medicament of claim 9, wherein the pharmaceutically acceptable carrier comprises distilled water, physiological saline, and phosphate buffer; in the medicine, the concentration of the compound polysaccharide preparation is more than or equal to 120 mug/mL.

Description

Composite polysaccharide preparation for treating diabetes and application thereof Technical Field The invention belongs to the technical field of biomedicine, and particularly relates to a compound polysaccharide preparation for treating diabetes and application thereof. Background Diabetes is a common chronic metabolic disease characterized by abnormally elevated blood glucose levels. Among diabetics, type 2 diabetes (Type 2 Diabetes Mellitus,T2DM) accounts for about 90% or more of the total adult diabetes. The disease is mainly caused by the gradual failure of insulin resistance combined with islet beta cell function, is frequently caused by middle-aged and elderly people, and is closely related to obesity, sedentary life style, heredity and environmental factors. Patients often have no obvious symptoms at early stages, but long-term hyperglycemia can lead to a variety of serious complications, such as cardiovascular disease, nephropathy, retinopathy, neuropathy, and the like. Traditional type 2 diabetes treatment relies primarily on lifestyle interventions in combination with oral hypoglycemic agents and injectable drugs. The preferred drug is metformin (metformin), which acts by inhibiting hepatic glucose output, improving insulin sensitivity, and has the advantages of low cost, cardiovascular protection benefits and neutral or slight weight loss. However, metformin is often associated with gastrointestinal discomfort (e.g., diarrhea, nausea), a part of patients (especially renal insufficiency) are at risk of lactic acidosis, and the efficacy may be impaired after long-term use, failing to effectively reverse the disease progression. Polysaccharide compounds as a natural bioactive substance have attracted considerable attention in the field of diabetes treatment. The polysaccharide is derived from plants, microorganisms or marine organisms, and has biological activities of resisting oxidation, resisting inflammation, improving insulin sensitivity, regulating intestinal flora, slightly regulating immunity, etc. However, most of the existing polysaccharide preparations are single components, have low bioavailability and single action mechanism, and lack a compound optimal design for type 2 diabetes. Therefore, the development of a compound polysaccharide preparation for better realizing the safe and efficient treatment of type 2 diabetes is of great significance. Disclosure of Invention The invention aims to provide a compound polysaccharide preparation for treating diabetes and application thereof. In order to achieve the above purpose, the present invention provides the following technical solutions: in a first aspect, the present invention provides a complex polysaccharide preparation for the treatment of diabetes, the complex polysaccharide preparation being made of complex polysaccharide a, complex polysaccharide B; the compound polysaccharide A is prepared from okra fruits and chlorella through alkaline ultrasonic extraction, deproteinization, ultrafiltration fractionation and freeze drying; The compound polysaccharide B is prepared from grifola frondosa and black tiger palm fungus through alcohol extraction degreasing, enzymolysis, hot water extraction, alcohol precipitation and freeze drying; The mass ratio of the compound polysaccharide A to the compound polysaccharide B is 1-3:1-3. Preferably, the diabetes is type 2 diabetes. Preferably, the mass ratio of the compound polysaccharide A to the compound polysaccharide B is 1:1. Preferably, the preparation method of the compound polysaccharide A comprises the following steps: (1) Mixing okra fruit powder and chlorella powder according to a mass ratio of 3:1 to obtain mixed powder a; (2) Adding 0.1 mol/L NaOH solution according to the feed liquid ratio of 1:20-30 g/mL, performing ultrasonic treatment at 40-50 ℃ for 30-50 minutes, and centrifuging to collect supernatant; (3) Deproteinizing the supernatant and adjusting the pH to neutrality to obtain polysaccharide extract; (4) Filtering with ultrafiltration membrane with molecular weight cut-off of 100kDa, and collecting permeate; (5) And filtering the permeate through an ultrafiltration membrane with the molecular weight cutoff of 10kDa, collecting the retentate, and drying to obtain the compound polysaccharide A. Preferably, the preparation method of the compound polysaccharide B comprises the following steps: (a) Mixing grifola frondosa powder and black tiger palm fungus powder according to a mass ratio of 2:1 to obtain mixed powder b; (b) Reflux degreasing with 80% ethanol solution, and collecting residue; (c) Deionized water is added according to the ratio of 1:20-30 g/mL, the pH is adjusted to 5.0-6.0, and cellulase and papain are added for enzymolysis; (d) After enzyme deactivation, extracting with 95 ℃ hot water for 1 hour, centrifuging to obtain supernatant, concentrating, precipitating with 75% ethanol, collecting precipitate, and freeze-drying to obtain compound polysaccharide B. In a seco